Richard Huntington Douglas
Independent Chair of the BoardDr. Richard Huntington Douglas, Ph.D., has been an Independent Consultant and Advisor at Red SkyPartners LLC since 2011. Dr. Douglas has been an Independent Director of Novavax, Inc. since 2010 and Aldeyra Therapeutics, Inc. since September 14, 2016. He has served as Independent Non-Executive Chairman of the Board of MaxCyte, Inc. since October 2021 and Independent Non-Executive Director since February 12, 2018. Dr. Douglas joined the MaxCyte, Inc. in February 12, 2018. Dr. Douglas served as Senior Vice President of Corporate Development and Corporate Officer of Genzyme Corporation from 1989 to 2011 and was with Genzyme since 1989. He serves as a Director of Alderya Therapeutics. He chairs the University of Michigan Innovation Partnerships National Advisory Board. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team and was involved in numerous acquisitions, licenses, financings, joint ventures and strategic alliances. He was responsible for evaluating and acquiring new products, programs and companies for Genzyme. Prior to joining Genzyme, he served as a Director of New Product Development at Integrated Genetics. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in Science and Corporate Development capacities at Integrated Genetics. He also served as Integrated Genetic's Manager of Protein Chemistry Research. He has over many years of biotechnology experience. He has served as an executive director of Labyrinth Choir, Inc. He has been Independent Chair of the Board of Aldeyra Therapeutics, Inc., since June 8, 2017 which he joined in 2016. He served as a Director of Intercell USA, Inc. (formerly, Iomai Corporation) from January 2002 to 2008. Dr. Douglas serves as a member of the boards of University of Michigan Technology Transfer National Advisory Board. Dr. Douglas has a Post Doctoral Fellowship in Dr. Leroy Hood laboratory at the California Institute of Technology and received his Ph.D. in Biochemistry from University of California, Berkeley and has a BS in Chemistry from the University of Michigan.
Positions
- Company NameAldeyra Therapeutics, Inc.Stock CodeALDXPositionIndependent Chair of the BoardColleagues
- TCTodd C. BradyCEO, President & Director
- MAMichael AlfieriHead of Finance and Principal Financial & Accounting Officer
- DBDavid BurkeHead of Investor Relations
- ALAdam LazorchakDirector of Translational Sciences & Non-Clinical Development
- GMGary M. PhillipsIndependent Director
- BRBen R. BronsteinIndependent Director
- DMDarlene M. Deptula-HicksIndependent Director
- Company NameNovavax, Inc.Stock CodeNVAXPositionIndependent DirectorColleagues
- JCJohn Charles JacobsPresident, CEO & Director
- DMDavid M. MottChairman of the Board of Directors
- JPJames Patrick KellyExecutive VP, CFO & Treasurer
- MJMark J. CaseyExecutive VP, Chief Legal Officer & Corporate Secretary
- EOElaine O'HaraExecutive VP & Chief Strategy Officer
- RPRichard P. CrowleyExecutive VP & COO
- MGMargaret G. McGlynnIndependent Vice Chairman of the Board of Directors
- RJRichard J. RodgersIndependent Director
- RHRichard Huntington DouglasIndependent Director
- Company NameMaxCyte, Inc.Stock CodeMXCTPositionIndependent Non-Executive Chairman of the BoardColleagues
- MMMaher MasoudPresident, CEO & Executive Director
- RHRichard Huntington DouglasIndependent Non-Executive Chairman of the Board
- PAParmeet AhujaChief Financial Officer
- JGJay GelfmanChief Operations Officer
- AMAna-Paula Martins FernandesSenior Vice President of Global Sales
- SKSidharth KapileshwarChief Corporate Development Officer
- WWWilliam W. BrookeIndependent Non-Executive Director
- RHRekha HemrajaniIndependent Non-Executive Director
- PJPatrick J. BalthropIndependent Non-Executive Director
